2015
Chapter Twenty-Eight Retinoid Processing in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cultures
Fields MA, Bowrey HE, Gong J, Ablonczy Z, Del Priore LV. Chapter Twenty-Eight Retinoid Processing in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cultures. Progress In Nucleic Acid Research And Molecular Biology 2015, 134: 477-490. PMID: 26310172, PMCID: PMC8680204, DOI: 10.1016/bs.pmbts.2015.06.004.Peer-Reviewed Original ResearchConceptsRetinal pigment epitheliumRetinal degenerative diseasesAge-related macular degenerationDegenerative diseasesPluripotent stem cell (iPSC) technologyPromising clinical optionNative retinal pigment epitheliumRetinal degenerative disordersStem cell-derived retinal pigment epitheliumStem cell technologyVisual functionMacular degenerationPigment epitheliumRetinoid processingClinical optionDegenerative disordersClinical therapyCell therapyPluripotent stem cell-derived retinal pigment epitheliumVisual cycleRPE-specific proteinTherapyDiseaseStem cellsTrans retinol
2012
The Eye as a Target Organ for Stem Cell Therapy
Fields M, Hwang J, Gong J, Cai H, Del Priore L. The Eye as a Target Organ for Stem Cell Therapy. Stem Cell Biology And Regenerative Medicine 2012, 1-29. DOI: 10.1007/978-1-4614-5493-9_1.Peer-Reviewed Original ResearchAge-related macular degenerationRetinal pigment epitheliumRetinal degenerative diseasesStem cell therapyCell therapyRetinitis pigmentosaDegenerative diseasesCurrent clinical trialsPromising therapeutic optionNature of pathologyViable clinical optionReplacement therapyTherapeutic optionsClinical trialsCell replacement therapyMacular degenerationRetinal disordersCellular disarrayPigment epitheliumTarget organsPharmaceutical treatmentClinical optionProgressive cellular dysfunctionRetinal degenerationTherapeutic interventions